Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$7.90
-0.30 (-3.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-4.4M · quality 41.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$44M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-56.5%
↓Gross Margin
-16.0%
↓Debt/Equity
0.99
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+74.1%
FCF CAGR
—
FCF margin
-637.2%
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $426301.0 · net income $-3.7M · FCF $-2.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $426301.00 | $426301.00 | $389850.00 | $181087.00 | $80717.00 |
| Net Income | $-3.7M | $-3.7M | $-6.0M | $-5.2M | $-7.4M |
| EBITDA | $-2.2M | $-2.2M | $-4.7M | $-4.4M | $-7.0M |
| EPS | -1.20 | -1.20 | -2.10 | -1.80 | -2.70 |
| Gross Margin | -16.0% | -16.0% | 69.5% | 110.6% | 66.8% |
| Operating Margin | -1081.9% | -1081.9% | -1438.8% | -2911.5% | -9155.2% |
| Net Margin | -870.8% | -870.8% | -1548.3% | -2868.5% | -9106.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.99 | 0.99 | 0.29 | 0.13 | 0.01 |
| Current Ratio | 0.12 | 0.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.7M | $-2.7M | $-4.4M | $-4.4M | $-11.7M |
| Returns | |||||
| ROE | -56.5% | -56.5% | -63.0% | -39.3% | -45.9% |
| Valuation | |||||
| P/B | 3.85 | 3.85 | 2.15 | 1.19 | 1.85 |
| Growth & Yield | |||||
| Revenue Growth | 9.4% | 9.4% | 115.3% | 124.3% | — |
| EPS Growth | 42.9% | 42.9% | -16.7% | 33.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+69.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.10 → -1.20
Residual
+69.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.